The DOI matches its Crossref record; the references it cites are not checked yet.
Sleepwalking Associated with Reboxetine in a Young Female Patient with Major Depression: A Case Report
Abstract
Several psychotropic compounds are known to influence the sleep-EEG. In very rare cases sleep abnormalities like parasomnia or arousal disorders have additionally been reported during psychotropic drug treatment. We report the case of a 19-year old female patient with a depressive episode and intermittent somnambulism under treatment with reboxetine. The patient with a history of somnambulism in early childhood again suffered from episodes of somnabulism which disappeared after a dose reduction of the drug. In patients having a predisposition for developing parasomnia, a treatment with reboxetine might induce somnambulism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The appearance of sleepwalking has been associated with other antidepressants, including Bupropion, Mirtazapine, and Reboxetine.
“The appearance of SW has also been associated with other AD, like Bupropion [114,115], Mirtazapine [116], and Reboxetine [117].”
From Diagnosis and Management of NREM Sleep Parasomnias in Children and Adults (2023) · cites this paper as [117]
Citations
The citation lists haven’t been fetched yet
Cited by 18
Metadata
- Authors
- Künzel, H. E., Schuld, A., & Pollmächer, T.
- Affiliations
- Max Planck Society (DE)
- ORCID
- Pollmächer, T.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-11
- Volume
- 37
- Issue
- 6
- Pages
- 307-308
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2011518792
- Cited by
- 18
- References
- 0
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 3
- FWCI
- 0.94
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- reboxetine, sleepwalking, parasomnias, major depressive disorder, antidepressant side effects, sleep EEG, dose reduction, young female patient
- MeSH terms
- Reboxetine, Adolescent, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Female, Humans, Morpholines, Personality Inventory, Psychiatric Status Rating Scales, Somnambulism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
